HDB-82 / BNJ Biopharma, Handok - LARVOL DELTA

HDB-82: A promising PROTAC degrader for KRAS G12D mutant cancers (AACR 2025) - "Intravenous administration of HDB-82 (10 mg/kg, q.w.) resulted in substantial tumor growth inhibition across multiple KRAS G12D-positive tumor models. These findings establish HDB-82 as a promising therapeutic candidate for KRAS G12D-mutant cancers, warranting further preclinical investigation and potential clinical development."

Oncology • Solid Tumor • KRAS